Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

Prostate cancer is the most common cancer in American men, with an estimated 333,830 new cases and 36,320 deaths projected for 2026 for the disease, according to the American Cancer ...

When it comes to detecting cancer, you want the fastest detection possible in order to treat it accurately and in a timely ...

Prostate Scotland is encouraging men across Scotland to start a simple but potentially life-saving conversation about ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Prostate cancer usually starts to grow on the outer part of the prostate, which means it doesn't press on the tube that ...

ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?

Free prostate cancer screening for men 40+ on Saturday, March 21, 10 a.m.–2 p.m. at Pike County Health Department in Troy; walk-ins only, no appointments needed.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...